Table 7.
MRI data
| MRI | Total n = (available scans) | RRMS | SPMS | NMO/NMOSD |
|---|---|---|---|---|
| Cerebral T2 lesions | ||||
| Baseline | (150) | (76) | (57) | (17) |
| New lesions within 1st year | 18 (137) | 6 (68) | 8 (51) | 4 (18) |
| New lesions within 2nd year | 6 (105) | 3 (46) | 2 (42) | 1 (17) |
| New lesions within 3rd year | 6 (74) | 3 (34) | 3 (29) | 0 (11) |
| Cerebral Gd+ lesions | ||||
| Baseline | 31 (150) | 24 (76) | 6 (57) | 1 (17) |
| New Gd+ lesions within 1st year | 5 (136) | 3 (68) | 2 (51) | 0 (18) |
| New Gd+ lesions within 2nd year | 1 (103) | 0 (46) | 1 (42) | 0 (17) |
| New Gd+ lesions within 3rd year | 1 (72) | 1 (34) | 0 (29) | 0 (11) |
| Cervical T2 lesions | ||||
| Baseline | (141) | (66) | (54) | (21) |
| New lesions within 1st year | 4 (130) | 1 (62) | 1 (50) | 1 (18) |
| New lesions within 2nd year | 3 (100) | 2 (46) | 1 (39) | 0 (15) |
| New lesions within 3rd year | 3 (74) | 0 (34) | 1 (29) | 0 (11) |
| Cervical Gd+ lesions | ||||
| Baseline | 35 (72) | 16 (66) | 10 (54) | 9 (21) |
| New Gd+ lesions within 1st year | 2 (127) | 0 (62) | 0 (50) | 2 (18) |
| New Gd+ lesions within 2nd year | 1 (99) | 0 (46) | 0 (39) | 1 (15) |
| New Gd+ lesions within 3rd year | 2 (74) | 1 (34) | 0 (29) | 1 (11) |
Gd+ gadolinium enhancing, n indicates the total number of patients with new lesions compared to previously available MRI. T2 and Gd+ lesions were counted separately, NMO neuromyelitis optica, NMOSD neuromyelitis optica spectrum disease, RRMS relapsing–remitting MS, SPMS secondary progressive MS